Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Alzheimers Dement ; 20(4): 3074-3079, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38324244

RESUMO

This perspective outlines the Artificial Intelligence and Technology Collaboratories (AITC) at Johns Hopkins University, University of Pennsylvania, and University of Massachusetts, highlighting their roles in developing AI-based technologies for older adult care, particularly targeting Alzheimer's disease (AD). These National Institute on Aging (NIA) centers foster collaboration among clinicians, gerontologists, ethicists, business professionals, and engineers to create AI solutions. Key activities include identifying technology needs, stakeholder engagement, training, mentoring, data integration, and navigating ethical challenges. The objective is to apply these innovations effectively in real-world scenarios, including in rural settings. In addition, the AITC focuses on developing best practices for AI application in the care of older adults, facilitating pilot studies, and addressing ethical concerns related to technology development for older adults with cognitive impairment, with the ultimate aim of improving the lives of older adults and their caregivers. HIGHLIGHTS: Addressing the complex needs of older adults with Alzheimer's disease (AD) requires a comprehensive approach, integrating medical and social support. Current gaps in training, techniques, tools, and expertise hinder uniform access across communities and health care settings. Artificial intelligence (AI) and digital technologies hold promise in transforming care for this demographic. Yet, transitioning these innovations from concept to marketable products presents significant challenges, often stalling promising advancements in the developmental phase. The Artificial Intelligence and Technology Collaboratories (AITC) program, funded by the National Institute on Aging (NIA), presents a viable model. These Collaboratories foster the development and implementation of AI methods and technologies through projects aimed at improving care for older Americans, particularly those with AD, and promote the sharing of best practices in AI and technology integration. Why Does This Matter? The National Institute on Aging (NIA) Artificial Intelligence and Technology Collaboratories (AITC) program's mission is to accelerate the adoption of artificial intelligence (AI) and new technologies for the betterment of older adults, especially those with dementia. By bridging scientific and technological expertise, fostering clinical and industry partnerships, and enhancing the sharing of best practices, this program can significantly improve the health and quality of life for older adults with Alzheimer's disease (AD).


Assuntos
Doença de Alzheimer , Isotiocianatos , Estados Unidos , Humanos , Idoso , Doença de Alzheimer/terapia , Inteligência Artificial , Gerociência , Qualidade de Vida , Tecnologia
2.
Comput Biol Med ; 170: 107951, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-38219646

RESUMO

The clinical observation and assessment of extra-ocular movements is common practice in assessing neurodegenerative disorders but remains observer-dependent. In the present study, we propose an algorithm that can automatically identify saccades, fixation, smooth pursuit, and blinks using a non-invasive eye tracker. Subsequently, response-to-stimuli-derived interpretable features were elicited that objectively and quantitatively assess patient behaviors. The cohort analysis encompasses persons with mild cognitive impairment (MCI), Alzheimer's disease (AD), Parkinson's disease (PD), Parkinson's disease mimics (PDM), and controls (CTRL). Overall, results suggested that the AD/MCI and PD groups had significantly different saccade and pursuit characteristics compared to CTRL when the target moved faster or covered a larger visual angle during smooth pursuit. These two groups also displayed more omitted antisaccades and longer average antisaccade latency than CTRL. When reading a text passage silently, people with AD/MCI had more fixations. During visual exploration, people with PD demonstrated a more variable saccade duration than other groups. In the prosaccade task, the PD group showed a significantly smaller average hypometria gain and accuracy, with the most statistical significance and highest AUC scores of features studied. The minimum saccade gain was a PD-specific feature different from CTRL and PDM. These features, as oculographic biomarkers, can be potentially leveraged in distinguishing different types of NDs, yielding more objective and precise protocols to diagnose and monitor disease progression.


Assuntos
Doença de Alzheimer , Doença de Parkinson , Humanos , Movimentos Oculares , Doença de Parkinson/diagnóstico , Movimentos Sacádicos , Doença de Alzheimer/diagnóstico , Piscadela
3.
Comput Biol Med ; 166: 107559, 2023 Oct 12.
Artigo em Inglês | MEDLINE | ID: mdl-37852107

RESUMO

Speech-based approaches for assessing Parkinson's Disease (PD) often rely on feature extraction for automatic classification or detection. While many studies prioritize accuracy by using non-interpretable embeddings from Deep Neural Networks, this work aims to explore the predictive capabilities and language robustness of both feature types in a systematic fashion. As interpretable features, prosodic, linguistic, and cognitive descriptors were adopted, while x-vectors, Wav2Vec 2.0, HuBERT, and TRILLsson representations were used as non-interpretable features. Mono-lingual, multi-lingual, and cross-lingual machine learning experiments were conducted leveraging six data sets comprising speech recordings from various languages: American English, Castilian Spanish, Colombian Spanish, Italian, German, and Czech. For interpretable feature-based models, the mean of the best F1-scores obtained from each language was 81% in mono-lingual, 81% in multi-lingual, and 71% in cross-lingual experiments. For non-interpretable feature-based models, instead, they were 85% in mono-lingual, 88% in multi-lingual, and 79% in cross-lingual experiments. Firstly, models based on non-interpretable features outperformed interpretable ones, especially in cross-lingual experiments. Specifically, TRILLsson provided the most stable and accurate results across tasks and data sets. Conversely, the two types of features adopted showed some level of language robustness in multi-lingual and cross-lingual experiments. Overall, these results suggest that interpretable feature-based models can be used by clinicians to evaluate the deterioration of the speech of patients with PD, while non-interpretable feature-based models can be leveraged to achieve higher detection accuracy.

4.
Front Neurol ; 14: 1142642, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-36937510

RESUMO

Motor impairments are only one aspect of Parkinson's disease (PD), which also include cognitive and linguistic impairments. Speech-derived interpretable biomarkers may help clinicians diagnose PD at earlier stages and monitor the disorder's evolution over time. This study focuses on the multilingual evaluation of a composite array of biomarkers that facilitate PD evaluation from speech. Hypokinetic dysarthria, a motor speech disorder associated with PD, has been extensively analyzed in previously published studies on automatic PD evaluation, with a relative lack of inquiry into language and task variability. In this study, we explore certain acoustic, linguistic, and cognitive information encoded within the speech of several cohorts with PD. A total of 24 biomarkers were analyzed from American English, Italian, Castilian Spanish, Colombian Spanish, German, and Czech by conducting a statistical analysis to evaluate which biomarkers best differentiate people with PD from healthy participants. The study leverages conceptual robustness as a criterion in which a biomarker behaves the same, independent of the language. Hence, we propose a set of speech-based biomarkers that can effectively help evaluate PD while being language-independent. In short, the best acoustic and cognitive biomarkers permitting discrimination between experimental groups across languages were fundamental frequency standard deviation, pause time, pause percentage, silence duration, and speech rhythm standard deviation. Linguistic biomarkers representing the length of the narratives and the number of nouns and auxiliaries also provided discrimination between groups. Altogether, in addition to being significant, these biomarkers satisfied the robustness requirements.

5.
Sci Rep ; 9(1): 19066, 2019 12 13.
Artigo em Inglês | MEDLINE | ID: mdl-31836744

RESUMO

Literature documents the impact of Parkinson's Disease (PD) on speech but no study has analyzed in detail the importance of the distinct phonemic groups for the automatic identification of the disease. This study presents new approaches that are evaluated in three different corpora containing speakers suffering from PD with two main objectives: to investigate the influence of the different phonemic groups in the detection of PD and to propose more accurate detection schemes employing speech. The proposed methodology uses GMM-UBM classifiers combined with a technique introduced in this paper called phonemic grouping, that permits observation of the differences in accuracy depending on the manner of articulation. Cross-validation results reach accuracies between 85% and 94% with AUC ranging from 0.91 to 0.98, while cross-corpora trials yield accuracies between 75% and 82% with AUC between 0.84 and 0.95, depending on the corpus. This is the first work analyzing the generalization properties of the proposed approaches employing cross-corpora trials and reaching high accuracies. Among the different phonemic groups, results suggest that plosives, vowels and fricatives are the most relevant acoustic segments for the detection of PD with the proposed schemes. In addition, the use of text-dependent utterances leads to more consistent and accurate models.


Assuntos
Doença de Parkinson/fisiopatologia , Fonética , Fala/fisiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Área Sob a Curva , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Espectrografia do Som
6.
PLoS One ; 8(7): e69043, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23874860

RESUMO

Addictions to illicit drugs are among the nation's most critical public health and societal problems. The current opioid prescription epidemic and the need for buprenorphine/naloxone (Suboxone®; SUBX) as an opioid maintenance substance, and its growing street diversion provided impetus to determine affective states ("true ground emotionality") in long-term SUBX patients. Toward the goal of effective monitoring, we utilized emotion-detection in speech as a measure of "true" emotionality in 36 SUBX patients compared to 44 individuals from the general population (GP) and 33 members of Alcoholics Anonymous (AA). Other less objective studies have investigated emotional reactivity of heroin, methadone and opioid abstinent patients. These studies indicate that current opioid users have abnormal emotional experience, characterized by heightened response to unpleasant stimuli and blunted response to pleasant stimuli. However, this is the first study to our knowledge to evaluate "true ground" emotionality in long-term buprenorphine/naloxone combination (Suboxone™). We found in long-term SUBX patients a significantly flat affect (p<0.01), and they had less self-awareness of being happy, sad, and anxious compared to both the GP and AA groups. We caution definitive interpretation of these seemingly important results until we compare the emotional reactivity of an opioid abstinent control using automatic detection in speech. These findings encourage continued research strategies in SUBX patients to target the specific brain regions responsible for relapse prevention of opioid addiction.


Assuntos
Buprenorfina , Emoções , Naloxona , Antagonistas de Entorpecentes , Tratamento de Substituição de Opiáceos , Transtornos Relacionados ao Uso de Opioides/diagnóstico , Fala , Comportamento Aditivo , Combinação Buprenorfina e Naloxona , Feminino , Humanos , Masculino
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...